# Appropriate Dosing to Optimise Personalised Cancer Treatments

> **NCT04154163** · — · COMPLETED · sponsor: **University of Dundee** · enrollment: 18 (actual)

## Conditions studied

- Melanoma Stage III
- Melanoma Stage IV
- Ovarian Cancer
- Renal Cancer Stage III
- Renal Cancer Stage IV
- Lung Cancer, Non-small Cell

## Interventions

- **DIAGNOSTIC_TEST:** Dried blood Spot (DBS)
- **DIAGNOSTIC_TEST:** Venous blood sampling

## Key facts

- **NCT ID:** NCT04154163
- **Lead sponsor:** University of Dundee
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-10
- **Primary completion:** 2021-03-05
- **Final completion:** 2021-03-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04154163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04154163, "Appropriate Dosing to Optimise Personalised Cancer Treatments". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04154163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*